Drug Insights

Is Selinexor approved by the FDA?

21 June 2024
3 min read

Yes, selinexor, marketed under the brand name Xpovio, is FDA approved. The U.S. Food and Drug Administration (FDA) granted approval for selinexor on an accelerated basis on July 3, 2019. This approval is based on the medication's ability to meet an unmet medical need in patients with specific types of cancer.

What is Selinexor?

Selinexor is an oral medication used in combination with other drugs to treat multiple myeloma and certain types of diffuse large B-cell lymphoma (DLBCL) in adults. It is a selective inhibitor of nuclear export (SINE) compound, classified under miscellaneous antineoplastics.

Uses of Selinexor

  1. Multiple Myeloma:
    • In combination with bortezomib and dexamethasone for patients who have received at least one prior therapy.
    • In combination with dexamethasone for patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
  2. Diffuse Large B-Cell Lymphoma (DLBCL):
    • For the treatment of relapsed or refractory DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

How is Selinexor Administered?

Selinexor is available in oral tablet forms with various dosing schedules, including once or twice weekly administration, depending on the specific regimen and combination with other medications. Dosages must be carefully followed as prescribed by a healthcare provider.

Common Side Effects

Selinexor can cause a range of side effects, some of which can be serious or fatal. Common side effects include:

  • Double vision, blurred vision, sensitivity to light or glare
  • Tiredness
  • Numbness, tingling, or burning pain in hands or feet
  • Anemia, bruising or bleeding
  • Increased blood sugar
  • Fever, infections, cold or flu symptoms
  • Changes in sodium and mineral levels
  • Abnormal liver or kidney function tests
  • Nausea, vomiting, loss of appetite
  • Diarrhea, constipation
  • Weight loss
  • Shortness of breath

Serious side effects may include blurred vision, severe nausea, loss of appetite, confusion, symptoms of sepsis, signs of infection, and low sodium levels.

Warnings and Precautions

  • Infection Risk: Patients may get infections more easily, including serious or fatal infections.
  • Low Platelet Counts: Can cause unusual bruising or bleeding.
  • Reproductive Health: Selinexor can harm an unborn baby; effective birth control is required for both men and women using this medication.

Drug Interactions

Selinexor can interact with other medications, including prescription and over-the-counter drugs, vitamins, and herbal products. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions.

Conclusion

Selinexor (Xpovio) received FDA approval on July 3, 2019, for treating multiple myeloma and diffuse large B-cell lymphoma. As with all medications, it is crucial to follow the prescribed dosage and administration instructions and to be aware of potential side effects and interactions with other drugs.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Kira Pharmaceuticals Presents Positive KP104 Phase 2 PNH Results at 2024 EHA Congress: Safety and Effectiveness
Latest Hotspot
3 min read
Kira Pharmaceuticals Presents Positive KP104 Phase 2 PNH Results at 2024 EHA Congress: Safety and Effectiveness
21 June 2024
Kira Pharmaceuticals Shares Encouraging KP104 Phase 2 PNH Trial Outcomes at 2024 EHA Congress, Highlighting Sustained Safety and Effectiveness.
Read →
Is Bremelanotide approved by the FDA?
Drug Insights
3 min read
Is Bremelanotide approved by the FDA?
21 June 2024
bremelanotide, marketed under the brand name Vyleesi, is FDA approved. The FDA granted approval for bremelanotide on June 21, 2019.
Read →
Subcutaneous Amivantamab BLA Submitted to U.S. FDA for EGFR-Mutant Non-Small Cell Lung Cancer
Latest Hotspot
3 min read
Subcutaneous Amivantamab BLA Submitted to U.S. FDA for EGFR-Mutant Non-Small Cell Lung Cancer
21 June 2024
A Biologics License Application for subcutaneous amivantamab was submitted to the U.S. FDA for people with non-small cell lung cancer with EGFR mutations.
Read →
Eli Lilly: GLP-1R/GCGR/GIPR Triagonist Reduces Liver Fat Content by 86%
Hot Spotlight
5 min read
Eli Lilly: GLP-1R/GCGR/GIPR Triagonist Reduces Liver Fat Content by 86%
20 June 2024
The study indicated that Retatrutide (LY3437943), a GLP-1R-related triple receptor agonist currently under clinical development, demonstrated significant efficacy and favorable safety in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.